Progestin

Phase 3Small molecule

WWashington University School of Medicine

Progestin is one of 13 small molecule programs targeting Endometrial Neoplasms. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Endometrial NeoplasmsNot yet recruiting

Ovarian StimulationNot yet recruiting

Endometrial NeoplasmsPhase 2

Not yet recruiting

Ovarian StimulationPhase 3

Not yet recruiting

Competition

Competitive Landscape

10 competitors in Ovarian Stimulation

#DrugCompanyPhaseTrials

Luveris

Merck & Co.

Phase 3

3 2

Progestin

WWashington University School of Medicine

Phase 3

1 3

Depo-Provera

Eli Lilly

Preclinical

1 4

Gynorest

SSolvay Pharmaceuticals

Preclinical

3 5

Trelstar

OOncoVerity, Inc.

Preclinical

1 6

Gonadotropin Releasing Hormone Antagonist

AAssiut University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Recruiting

Study completion

NCT05903131

Phase 2Not yet recruiting

Endometrial Neoplasms

NCT07714070

Clinical

Trials by Indication[1]

Endometrial1 trial

Progestin-induced Endometrial Shedding in PCOS (The PIES in PCOS Study)

Terminated·UUniversity of Illinois at Chicago·N/A·NCT01718444·27 enrolled

Ovulation Induction1 trial

Effect of Progestin-Induced Withdrawal Bleed on Ovulation Induction Cycles With Clomiphene Citrate

Withdrawn·UUniversity of British Columbia·Phase 4·NCT01966575

Ovarian Stimulation1 trial

Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes

Not yet recruiting·NNesta Clinic·Phase 4·NCT06396390·152 enrolled

Ovarian cyst1 trial

Treat of Functional Ovarian Cysts by Compare Between Cocs and Progesterone Only Pills

Unknown status·SSohag University·Phase 3·NCT05244811·60 enrolled

Endometrial Neoplasms1 trial

A Single-Center, Randomized, Open-Label, Controlled Trial of Orlistat Combined With Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Endometrial Hyperplasia With Low Progesterone Receptor Expression

Not yet recruiting·PPeking University People's Hospital·Phase 2·NCT07714070·48 enrolled

1 more indication

Unspecified2 trials

Uterine Preservation Via Lifestyle Transformation

Recruiting·WWashington University School of Medicine·Phase 2·NCT05903131·96 enrolled

Regulation of Cervical Mucus Secretion

Completed·OOregon Health and Science University·Phase 4·NCT02969590·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Progestin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Progestin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Progestin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: WWashington University School of Medicine

Progestin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Endometrial1 trial

Ovulation Induction1 trial

Ovarian Stimulation1 trial

Ovarian cyst1 trial

Endometrial Neoplasms1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News